These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8962270)

  • 1. Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine.
    Hale DA; Gottschalk R; Wood ML; Maki T; Monaco AP
    Transplant Proc; 1996 Dec; 28(6):3270-1. PubMed ID: 8962270
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.
    Hale DA; Gottschalk R; Maki T; Monaco AP
    Transplantation; 1997 Sep; 64(6):897-900. PubMed ID: 9326417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice.
    Stepkowski SM; Tu Y; Chou TC; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3025-7. PubMed ID: 7940952
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolongation of rat to mouse skin and heart xenograft survival by combined CTLA4Ig and anti-CD4/CD8 antibody.
    Tu Y; Rehman A; Flye MW
    Transplant Proc; 1996 Aug; 28(4):2061-2. PubMed ID: 8769156
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts.
    Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S
    Transplant Proc; 1999; 31(1-2):1244. PubMed ID: 10083555
    [No Abstract]   [Full Text] [Related]  

  • 6. CTLA4-Ig prolongs survival of microencapsulated rabbit islet xenografts in spontaneously diabetic Nod mice.
    Weber CJ; Hagler MK; Chryssochoos JT; Larsen CP; Pearson TC; Jensen P; Kapp JA; Linsley PS
    Transplant Proc; 1996 Apr; 28(2):821-3. PubMed ID: 8623418
    [No Abstract]   [Full Text] [Related]  

  • 7. Synergistic effect of immunosuppressive drug and intrathymic inoculation of donor cells in skin graft survival.
    Dono K; Wood ML; Ozato H; Monaco AP
    Transplant Proc; 1994 Oct; 26(5):3061. PubMed ID: 7940963
    [No Abstract]   [Full Text] [Related]  

  • 8. Extended skin allo- and xenograft survival in mice treated with rapamycin, antilymphocyte serum, and donor-specific bone marrow transfusion.
    Hale DA; Gottschalk R; Fukuzaki T; Wood ML; Maki T; Monaco AP
    Transplant Proc; 1996 Dec; 28(6):3269. PubMed ID: 8962269
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of rapamycin on islet and skin xenograft survival.
    Bobbio SA; Porter JG; Monaco AP
    Transplant Proc; 1993 Aug; 25(4):2745-6. PubMed ID: 8356733
    [No Abstract]   [Full Text] [Related]  

  • 10. Triple combination of cyclosporine, brequinar, and rapamycin prolongs kidney allograft survival in the mongrel dog.
    Ferraresso M; Knight R; Tu Y; Stepkowski SM; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3028. PubMed ID: 7940953
    [No Abstract]   [Full Text] [Related]  

  • 11. CD28-pathway blockade with CTLA4Ig leads to prolongation of small bowel transplant survival in rats.
    Pescovitz MD; Yang R; Liu Q; Collins MH; Grosfeld JL
    Transplant Proc; 1994 Jun; 26(3):1618-9. PubMed ID: 8030059
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts.
    Masri MA
    Transplant Proc; 1995 Feb; 27(1):366. PubMed ID: 7533412
    [No Abstract]   [Full Text] [Related]  

  • 13. Failure of combined costimulatory blockade in animal transplant model.
    Dharnidharka VR; Schowengerdt K; Skoda-Smith S
    Nat Med; 2000 Feb; 6(2):115. PubMed ID: 10655074
    [No Abstract]   [Full Text] [Related]  

  • 14. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow.
    Hale DA; Gottschalk R; Maki T; Monaco AP
    Transplantation; 1998 Feb; 65(4):473-9. PubMed ID: 9500619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of single-dose, late treatment with rapamycin on skin allograft survival in ALS- and donor bone marrow cell-treated mice.
    De Fazio SR; Plowey J; Hartner WC; Gozzo JJ
    Transplant Proc; 1994 Dec; 26(6):3102-3. PubMed ID: 7998084
    [No Abstract]   [Full Text] [Related]  

  • 16. Tolerance induction by soluble CTLA4 in a mouse skin transplant model.
    Tepper MA; Linsley PS; Tritschler D; Esselstyn JM
    Transplant Proc; 1994 Dec; 26(6):3151-4. PubMed ID: 7998099
    [No Abstract]   [Full Text] [Related]  

  • 17. Synergistic effect of 3M KCl-extracted donor antigens with cyclosporine or cyclosporine/rapamycin to prolong heart allograft survival in rats.
    Hamashima T; Stepkowski SM; Smith S; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3053-5. PubMed ID: 7940960
    [No Abstract]   [Full Text] [Related]  

  • 18. Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow.
    Hale DA; Gottschalk R; Fukuzaki T; Wood ML; Maki T; Monaco AP
    Transplantation; 1997 Feb; 63(3):359-64. PubMed ID: 9039923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolongation of rat small bowel allograft survival by CTLA-4 IG.
    Tarumi K; Yagihashi A; Murakami M; Uede T; Hirata K
    Transplant Proc; 1998 Sep; 30(6):2596-9. PubMed ID: 9745507
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined effect of rapamycin and cyclosporine in the prevention of rat corneal allograft rejection.
    Thompson P; Xu D; Brunette I; Chen H
    Transplant Proc; 1998 Jun; 30(4):1033-5. PubMed ID: 9636417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.